GR1008818B - Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου - Google Patents

Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου

Info

Publication number
GR1008818B
GR1008818B GR20150100238A GR20150100238A GR1008818B GR 1008818 B GR1008818 B GR 1008818B GR 20150100238 A GR20150100238 A GR 20150100238A GR 20150100238 A GR20150100238 A GR 20150100238A GR 1008818 B GR1008818 B GR 1008818B
Authority
GR
Greece
Prior art keywords
antifungal agent
preparation
pharmaceutical composition
composition containing
echinocandin antifungal
Prior art date
Application number
GR20150100238A
Other languages
English (en)
Inventor
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Αναστασια Λεωνιδα Καλασκανη
Βασιλικη Χρηστου Σαμαρα
Ανδρεας Κωνσταντινου Κακουρης
Γιωργος Θεμιστοκλη Γκοτζαμανης
Ευαγγελος Ανδρεα Καραβας
Χριστινα-Χρυση Ηλια Κιζιριδη
Original Assignee
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων filed Critical Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων
Priority to GR20150100238A priority Critical patent/GR1008818B/el
Priority to EP16728831.5A priority patent/EP3298026A1/en
Priority to PCT/EP2016/000840 priority patent/WO2016188625A1/en
Publication of GR1008818B publication Critical patent/GR1008818B/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Η παρούσα εφεύρεση αφορά υδατικό διάλυμα περιέχον έναν αντιμυκητιασιακό παράγοντα εχινοκανδίνης, όπως η οξική Κασποφουνγκίνη, ως δραστική ουσία, ένα ρυθμιστικό μέσο και τουλάχιστον ένα αραιωτικό/διογκωτικό. Επίσης, αφορά τη λυοφιλοποίηση τέτοιου διαλύματος, ώστε να ανακτηθεί μια ξηρή κόνις για ανασύσταση πριν τη χρήση.
GR20150100238A 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου GR1008818B (el)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GR20150100238A GR1008818B (el) 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
EP16728831.5A EP3298026A1 (en) 2015-05-22 2016-05-20 Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof
PCT/EP2016/000840 WO2016188625A1 (en) 2015-05-22 2016-05-20 Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20150100238A GR1008818B (el) 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου

Publications (1)

Publication Number Publication Date
GR1008818B true GR1008818B (el) 2016-08-01

Family

ID=56121013

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20150100238A GR1008818B (el) 2015-05-22 2015-05-22 Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου

Country Status (3)

Country Link
EP (1) EP3298026A1 (el)
GR (1) GR1008818B (el)
WO (1) WO2016188625A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
BRPI0009249B8 (pt) 1999-03-03 2021-07-06 Lilly Co Eli formulação farmacêutica parenteral de equinocandina contendo tensoativos de formação de micela.
CA2692053A1 (en) * 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
KR20130136466A (ko) * 2010-09-20 2013-12-12 셀리아 파마슈티칼즈 에이피에스 카스포펀진 조성물
CN103212058A (zh) * 2012-01-18 2013-07-24 江苏恒瑞医药股份有限公司 含有抗真菌药物和乳酸盐缓冲剂的组合物
CN103315966B (zh) * 2013-06-18 2016-01-13 江苏奥赛康药业股份有限公司 一种注射用醋酸卡泊芬净药物组合物及其制备方法

Also Published As

Publication number Publication date
WO2016188625A9 (en) 2017-04-27
WO2016188625A1 (en) 2016-12-01
EP3298026A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
PH12014502778A1 (en) Antibody formulation
MY187047A (en) Selective pyy compounds and uses thereof
HK1250714A1 (zh) 雜芳基衍生物或其藥學上可接受的鹽、其製備方法以及包含其作為活性成分的用於預防或治療pi3激酶相關疾病的藥物組合物
EP3659585A4 (en) COMPOSITION FOR ADMINISTERING PHYSIOLOGICALLY ACTIVE SUBSTANCES INTO A BLOOD VESSEL
MY185802A (en) Antibody formulation
MX2018001006A (es) Composicion farmaceutica que comprende un vector adenoviral.
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
WO2015058173A8 (en) Stable solid units and methods of making the same
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
IN2013MU03583A (el)
MX2016001422A (es) Composicion farmaceutica de fingolimod.
TW201613557A (en) Stable aqueous recombinant protein formulations
PH12017502322A1 (en) Therapeutic agent for fibrosis
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
EP3192368A4 (en) Composition for preserving cells, containing, as active ingredients, plant-derived recombinant human serum albumin and plant peptides
GR1008234B (el) Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου
EP3388446A4 (en) IMPROVED ANGIOGENESIS-INHIBITING PEPTIDE AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF ANGIOGENIC DISEASES THEREOF AS AN ACTIVE SUBSTANCE
GR1008818B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
EP3323411A4 (en) Composition for inhibiting angiogenesis containing nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof
IN2014MU00284A (el)
EP3603659A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE, BASED ON CELL PERMEABLE PEPTIDE FUSION PROTEIN AND CTCTLA4 PEPTIDE, CONTAINED AS ACTIVE INGREDIENT IN THIS COMPOSITION
MD20170094A2 (ro) Procedeu de fabricare a amestecurilor de pulbere uscată
PH12018501392A1 (en) Pharmaceutical composite preparation

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20160921